Francisco Bracho, MD

Attending Physician; Hematology, Oncology and Blood and Marrow Transplantation
Associate Professor of Clinical Pediatrics, Keck School of Medicine of USC

Dr. Bracho is fluent in Spanish. He received his medical degree from the University of California Los Angeles School of Medicine. Following his residency at Los Angeles County University of Southern California Women's and Children's Hospital, he started a fellowship in pediatric hematology/oncology at Children's Hospital Orange County.

He relocated and completed his fellowship at Georgetown University Medical Center Washington, D.C. under the umbrella of the National Cancer Institute. He has diverse expertise in areas including cord blood transplant, hereditary angioedema and white cell diseases.

Education

Medical School

University of California Los Angeles School of Medicine

Internship

Pediatrics: Los Angeles County+University of Southern California Medical Center

Residency

Pediatrics: Los Angeles County+University of Southern California Medical Center

Fellowship

Pediatric Hematology/Oncology: Children's Hospital of Orange County and National Cancer Institute

Accomplishments

Certification

Pediatrics and Pediatric Hematology Oncology: American Board of Pediatrics

Memberships

Academic Honors: Alpha Omega Alpha Society and Phi Beta Kappa Society

Publications

Publications

Marco Cicardi, M.D., Aleena Banerji, M.D., Francisco Bracho, M.D.,et al. Icatibant, a New Bradykinin-Receptor Antagonist in Hereditary Angioedema N Engl J Med 2010 363:532-541

Bracho F, van de Ven C, Areman E, Hughes RM, Davenport V, Bradley MB, Cai JW, Cairo MS. A comparison of ex vivo expanded DCs derived from cord blood and mobilized adult peripheral blood plastic-adherent mononuclear cells: decreased alloreactivity of cord blood DCs. Cytotherapy. 2003 5(5):349-61

Bracho F, Krailo MD, Shen V. Bergeron S, Davenport V, Liu-Marces W, Blazer BR, Panoskaltsis-Mortari A. van de Ven C, Secola R, Ames MM, Reid JM, Reaman GH, Cairo MS. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. Clin Cancer Res. 2001 Jan 7(1):58-67

M. Cairo and F. Bracho, “White blood cells.” In: C. Rudolph, A.M. Rudolph and M.K. Hostetter et al., Editors, Rudolph's Pediatrics (21st ed. 2003 McGraw Hill, New York)

Research

Research Summary

K-12 principal investigator for angioedema subcutaneous treatments